CIK 0001601485 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Elicio Therapeutics, Inc.
Sign in to watch- Ticker
- ELTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113430072
- Phone
- (857) 209-0050
- Business address
- 451 D STREET, 5TH FLOOR, BOSTON, MA, 02210
- Former names
- Angion Biomedica Corp.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-31 | Chudnovsky Yekaterina Director | Grant or award · Stock Option (Right to Buy) | +21,750 | 21,750 | ||
| 2026-08-31 | Ashe Carol Gail Director | Grant or award · Stock Option (Right to Buy) | +21,750 | 21,750 | ||
| 2026-08-31 | Nissenson Allen Director | Grant or award · Stock Option (Right to Buy) | +21,750 | 21,750 | ||
| 2026-08-31 | Venkatesan Jay Director | Grant or award · Stock Option (Right to Buy) | +21,750 | 21,750 | ||
| 2026-08-31 | WILSON KAREN J Director | Grant or award · Stock Option (Right to Buy) | +21,750 | 21,750 | ||
| 2026-08-31 | ADAMS JULIAN Director | Grant or award · Stock Option (Right to Buy) | +21,750 | 21,750 | ||
| 2026-08-31 | RUFFOLO ROBERT R Director | Grant or award · Stock Option (Right to Buy) | +21,750 | 21,750 | ||
| 2026-07-16 | DeMuth Peter Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +52,832 | 52,832 | ||
| 2026-07-16 | Connelly Robert CEO, President and Director | Grant or award · Stock Option (Right to Buy) | +186,944 | 186,944 | ||
| 2026-07-16 | Shah Preetam See Remarks | Grant or award · Stock Option (Right to Buy) | +60,833 | 60,833 | ||
| 2026-07-16 | Haqq Christopher See Remarks | Grant or award · Stock Option (Right to Buy) | +64,643 | 64,643 | ||
| 2026-02-02 | Connelly Robert CEO, President and Director | Grant or award | +73,600 | 120,570 | ||
| 2026-02-02 | Connelly Robert CEO, President and Director | Grant or award · Stock Option (Right to Buy) | +147,200 | 147,200 | ||
| 2026-02-02 | Shah Preetam See Remarks | Grant or award | +24,000 | 24,000 | ||
| 2026-02-02 | Shah Preetam See Remarks | Grant or award · Stock Option (Right to Buy) | +47,900 | 47,900 | ||
| 2026-02-02 | DeMuth Peter Chief Scientific Officer | Grant or award | +20,800 | 21,543 | ||
| 2026-02-02 | DeMuth Peter Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +41,600 | 41,600 | ||
| 2026-02-02 | Haqq Christopher See Remarks | Grant or award | +25,400 | 57,381 | ||
| 2026-02-02 | Haqq Christopher See Remarks | Grant or award · Stock Option (Right to Buy) | +50,900 | 50,900 | ||
| 2025-12-09 | DeMuth Peter Chief Scientific Officer | Option exercise | +362 | $4.41 | $2K | 743 |
Page 1 of 9 · 171 trades